|
2026 Journal Article Microbiological outcomes associated with Burkholderia species in people with cystic fibrosis receiving CFTR modulator therapyRiddles, Timothy, Smith, Daniel, Reid, David W., Henderson, Daniel, Blanco, Arianne J., Moore, Vanessa, Wood, Michelle and Evans, Ieuan E. S. (2026). Microbiological outcomes associated with Burkholderia species in people with cystic fibrosis receiving CFTR modulator therapy. Journal of Cystic Fibrosis. doi: 10.1016/j.jcf.2026.03.011 |
|
2026 Journal Article Treatment outcomes and safety of clofazimine in nontuberculous mycobacterial pulmonary disease (NTM-PD)Kang, Shaun J. W., Watt, Adrian, Wilson, Malcolm R., Eather, Geoffrey W., Baird, Timothy, Evans, Ieuan E. S., Burke, Andrew J. and Thomson, Rachel M. (2026). Treatment outcomes and safety of clofazimine in nontuberculous mycobacterial pulmonary disease (NTM-PD). Mycobacteria, 2 (1) 1. doi: 10.1186/s44350-026-00012-1 |
|
2025 Journal Article Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guardEvans, Ieuan Edward Shepherd, Smith, Daniel, Henderson, Daniel, Riddles, Timothy, Masel, Philip, Moore, Vanessa, Burke, Andrew J., Thomson, Rachel M. and Reid, David W. (2025). Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. BMJ Open Respiratory Research, 12 (1) e003204, 1-9. doi: 10.1136/bmjresp-2025-003204 |
|
2025 Journal Article In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolatesPatterson-Fahy, Kirby, Carter, Robyn, Bell, Scott C., Evans, Ieuan E. S., Burke, Andrew John and Thomson, Rachel M. (2025). In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates. Journal of Antimicrobial Chemotherapy, 81 (1) dkaf441, 1-9. doi: 10.1093/jac/dkaf441 |
|
2025 Journal Article Metabolic control of porin permeability influences antibiotic resistance in Escherichia coliCaño Muñiz, Santiago E., Trigg, Stephen, Hardo, Georgeos, Hagting, Anja, Evans, Ieuan E., Ruis, Christopher, Alsulami, Ali F., Summers, David, Crawshay-Williams, Felicity, Blundell, Tom L., Boeck, Lucas, Bakshi, Somenath and Floto, R. Andres (2025). Metabolic control of porin permeability influences antibiotic resistance in Escherichia coli. Nature Microbiology, 10 (12), 3202-3214. doi: 10.1038/s41564-025-02175-5 |
|
2025 Journal Article The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studiesEvans, Ieuan E. S., Duplancic, Christine M., Kidd, Timothy A., Ballard, Emma L., Thomson, Rachel M., Wainwright, Claire E. and Bell, Scott C. (2025). The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studies. Journal of Cystic Fibrosis, 24 (5), 903-908. doi: 10.1016/j.jcf.2025.07.002 |
|
2025 Journal Article Thoracic magnetic resonance imaging in non-tuberculous mycobacterial pulmonary disease: characteristics and potential implementationEvans, Ieuan Edward Shepherd, Baird, Timothy, Haworth, Charles S., Johnson, Christopher, Barker, Helen, Hill, Uta, Grogono, Dorothy, Eneje, Odiri, Screaton, Nicholas and Floto, Andres (2025). Thoracic magnetic resonance imaging in non-tuberculous mycobacterial pulmonary disease: characteristics and potential implementation. PLoS One, 20 (6) e0325347, 1-12. doi: 10.1371/journal.pone.0325347 |
|
2025 Journal Article Disproportionate rates of liver injury in people with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor in Queensland, AustraliaJohnson, Ellie, Riddles, Timothy, Smith, Daniel, Henderson, Daniel, Masel, Philip, Reid, David W., Moore, Vanessa and Evans, Ieuan E.S. (2025). Disproportionate rates of liver injury in people with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor in Queensland, Australia. Gastro Hep Advances, 4 (6) 100641, 1-4. doi: 10.1016/j.gastha.2025.100641 |
|
2025 Conference Publication Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary DiseaseTwining, M., Kang, S., Riddles, T., Evans, I., Burke, A.J. and Thomson, R. (2025). Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a5444 |
|
2025 Journal Article The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary diseaseMou, Claire Y., Henderson, Daniel J., Matson, Angela G., Herd, Karen M., Reid, David W., Riddles, Timothy, Johnson, Ellie, McWhinney, Brett, Swenson, Rebecca, Burke, Andrew and Evans, Ieuan E.S. (2025). The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease. European Clinical Respiratory Journal, 12 (1) 2458341, 1-5. doi: 10.1080/20018525.2025.2458341 |
|
2024 Journal Article Achromobacter xylosoxidans totally implantable venous access device infection in a person with cystic fibrosis: complex management considerationsEvans, Ieuan E. S., Haqqani, Haris, Smith, Daniel and Reid, David W. (2024). Achromobacter xylosoxidans totally implantable venous access device infection in a person with cystic fibrosis: complex management considerations. Respirology Case Reports, 12 (12) e70087, 1-4. doi: 10.1002/rcr2.70087 |
|
2024 Journal Article Phenotypic evaluation of rare cystic fibrosis transmembrane conductance regulator mutation combinations in people with cystic fibrosis in Queensland, AustraliaEvans, Ieuan Edward Shepherd, Wood, Michelle, Moore, Vanessa and Reid, David William (2024). Phenotypic evaluation of rare cystic fibrosis transmembrane conductance regulator mutation combinations in people with cystic fibrosis in Queensland, Australia. Journal of Clinical Medicine, 13 (20) 6210, 1-9. doi: 10.3390/jcm13206210 |
|
2024 Conference Publication Disproportionate rates of liver impairment in Australian cystic fibrosis patients initiated on elexacaftor/tezacaftor/ivacaftor (ETI)Johnson, Ellie, Evans, Ieuan and Reid, David (2024). Disproportionate rates of liver impairment in Australian cystic fibrosis patients initiated on elexacaftor/tezacaftor/ivacaftor (ETI). 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD, Australia, 2–4 August 2024. Richmond, VIC, Australia: John Wiley & Sons. |
|
2024 Journal Article Mycobacterium abscessus treatment outcomes in cystic fibrosis: a single centre experienceEvans, Ieuan, Weimann, Aaron, Baird, Timothy, Haworth, Charles and Floto, Andres (2024). Mycobacterium abscessus treatment outcomes in cystic fibrosis: a single centre experience. Journal of Cystic Fibrosis, 24 (2), 364-367. doi: 10.1016/j.jcf.2024.07.016 |
|
2024 Conference Publication Sodium intake of adults with cystic fibrosis living in north Queensland post elexacaftor-tezacaftor-ivacaftorHerd, Karen, Matson, Angela, Loel, Felicity, Moore, Vanessa and Evans, Ieuan (2024). Sodium intake of adults with cystic fibrosis living in north Queensland post elexacaftor-tezacaftor-ivacaftor. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD, Australia, 2–4 August 2024. Richmond, VIC, Australia: John Wiley & Sons. |
|
2024 Conference Publication Multi-centre experience of elexacaftor-tezacaftor-ivacaftor use in adult cystic fibrosis transplant recipients in QueenslandWood, Michelle, Smith, Iain, Hiscock, Keirran, Smith, Daniel, Keating, Rebecca, Burr, Lucy, Tay, George, Zimmerman, Maureen, Feather, Iain, Cobb, Robyn, Moore, Vanessa, Evans, Ieuan, Reid, David, Masel, Philip, Mackintosh, John and Henderson, Daniel (2024). Multi-centre experience of elexacaftor-tezacaftor-ivacaftor use in adult cystic fibrosis transplant recipients in Queensland. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD Australia, 2-4 August 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication Evaluating the outcomes of CFTR modulator therapy on the rates of non-tuberculous mycobacteria isolated from patients in a cystic fibrosis (CF) cohortEvans, Ieuan Edward Shepherd, Smith, Daniel and Reid, David William (2024). Evaluating the outcomes of CFTR modulator therapy on the rates of non-tuberculous mycobacteria isolated from patients in a cystic fibrosis (CF) cohort. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD Australia, 2–4 August 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication A prospective study analysing the CFTR modulator impact on innate immunity in cystic fibrosis airwayFernando, Amali, Jurak, Lisa, Essilfie, Ama-Tawiah, Wood, Michelle, Smith, Iain, Hiscock, Keirran, Cobb, Robyn, Moore, Vanessa, Henderson, Daniel, Evans, Ieuan, Smith, Daniel and Reid, David (2024). A prospective study analysing the CFTR modulator impact on innate immunity in cystic fibrosis airway. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD, Australia, 2–4 August 2024. Richmond, VIC, Australia: John Wiley & Sons. |
|
2024 Conference Publication Rifabutin induces Elexacaftor metabolism in Mycobacterium abscessus-related pulmonary disease: A case studyMattison, Graeme, Keating, Rebecca, McWhinney, Brett, Connors, Shannon, Swenson, Rebecca, Evans, Ieuan, Burke, Andrew and Burr, Lucy (2024). Rifabutin induces Elexacaftor metabolism in Mycobacterium abscessus-related pulmonary disease: A case study. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD Australia, 2–4 August 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication High prevalence of rare CFTR mutation phenotypes in people with cystic fibrosis in Queensland, AustraliaEvans, Ieuan and Reid, David (2024). High prevalence of rare CFTR mutation phenotypes in people with cystic fibrosis in Queensland, Australia. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD, Australia, 2–4 August 2024. Richmond, VIC, Australia: John Wiley & Sons. |
